You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION WITH LARGE SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION

Iacono, Pierluigi MD*; Parodi, Maurizio B. MD; Introini, Ugo MD; La Spina, Carlo MD; Varano, Monica MD*; Bandello, Francesco MD

Retina:
doi: 10.1097/IAE.0b013e3182979e33
Original Study
Abstract

Purpose: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration.

Methods: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features.

Results: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 µm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 µm (P < 0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered.

Conclusion: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

In Brief

Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

Author Information

*G. B. Bietti Foundation for Ophthalmology, Scientific Institute of Admission and Care, Rome, Italy; and

Department of Ophthalmology, Vita-Salute San Raffaele University, Milan, Italy.

Reprint requests: Pierluigi Iacono, MD, G. B. Bietti Foundation for Ophthalmology, Scientific Institute of Admission and Care, Via Livenza 3, 00198 Rome, Italy; e-mail: pierluigi.iacono@libero.it

F. Bandello is an Advisory Board member for Novartis Pharma. The other authors have no financial/conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.